Çocuk Nörologlarının Antiepileptik Tercihi: İstanbul Çocuk Nörolojisi Grubu Anket Çalışması

Öz

Amaç: Çocuk nörologlarının ilaç tercihlerini anket çalışmasıyla ortaya koymak. Yöntemler: Anket yenidoğan nöbetleri ve 10 farklı epileptik durum işaret eden vaka sunumlarını içermekteydi. Katılımcılardan bu durumlardaki ilk ilaç tercihleri, tedavi başarısızlığı durumunda ilaç ekleme veya ilaç değiştirme yaklaşımları sorgulandı. Bulgular: Yenidoğan nöbetlerinde tüm katılımcılar ilk tercih olarak fenobarbitali seçmişlerdi. Valproik asit katılımcıların miyoklonik astatik epilepside % 100’ünün, foto sensitif epilepside % 85’inin, absans epilepside % 74’ünün, uykudaki elektriksel statusta % 73’ünün ilk tercih ettikleri ilaç olmuştu. Kompleks parsiyel nöbetlerde valproik asit, karbamazepin ve okskarbazepin eşit oranda tercih edilmişti. Sonuç: Anket sonuçları çocuk nörologlarının fenobarbital, valproik asit ve karbamazepin gibi uzun yıllardır kullanılan antiepileptikleri daha çok tercih ettiklerini gösteriyo

Anahtar Kelimeler

• Epilepsi,antiepileptik ilaç,çocuk nöroloğu

Antiepileptic Choice of Pediatric Neurologists: Istanbul Pediatric Neurology Study Group Survey

Öz

Objective: To reveal antiepileptic drug preferences of the pediatric neurologist using questionnaire surveys. Methods: The survey included neonatal seizures and 10 different patients with specific epileptic conditions. Participants were asked for the first drug of choice and attitudes in the case of treatment failure. Results: In neonatal seizures, phenobarbital was the first choice of all participants. Valproate was the first choice of 100 % of the participants in myoclonic astatic epilepsy, of 85 % in photo-sensitive epilepsy, of 74 % in absence epilepsy, of 73 % in electrical status at slow sleep. For complex partial seizures, valproate, carbamazepine and oxcarbazepine were preferred equally. Conclusion: Results of the survey showed that drugs used for many years such as phenobarbital, valproic acid and carbamazepine are more preferred by pediatric neurologists

Anahtar Kelimeler

• Epilepsy,antiepileptic drugs,pediatric neurologist

Kaynakça

1. 1. Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol 2005;20(Suppl 1):1-56.
2. 2. Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007 Epileptic Disord 2007;9:353-412. PMid:18077226
3. 3. Neal EG, Chaffe H, Schwartz RH, et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol 2008;7:500-6. http://dx.doi.org/10.1016/S1474-4422(08)70092-9
4. 4. Hader WJ, Mackay M, Otsubo H, et al. Cortical dysplastic lesions in children with intractable epilepsy: role of complete resection. J Neurosurg 2004;100:110-7. PMid:14758938
5. 5. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47:1094- 120. http://dx.doi.org/10.1111/j.1528-1167.2006.00585.x PMid:16886973
6. 6. Booth D, Evans DJ. Anticonvulsants for neonates with seizures. Cochrane Database Syst Rev 2004;4:CD004218. PMid:15495087
7. 7. Levene M. The clinical conundrum of neonatal seizures. Arch Dis Child Fetal Neonatal Ed. 2002;86:75-7. http://dx.doi.org/10.1136/fn.86.2.F75 PMCid:1721380
8. 8. Kossoff EH. Infantile spasms. Neurologist 2010;16:69-75. http://dx.doi.org/10.1097/NRL.0b013e3181d1416c PMid:20220440

9. 9. Curatolo P, Seri S, Verdecchia M, Bombardieri R. Infantile spasms in tuberous sclerosis complex. Brain Dev 2001;23:502-7. http://dx.doi.org/10.1016/S0387-7604(01)00300-X
10. 10. Kälviäinen R, Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 2001;3:217-30.
11. 11. Kelley SA, Kossoff EH. Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress. Dev Med Child Neurol 2010;52:988-9. http://dx.doi.org/10.1111/j.1469-8749.2010.03744.x
12. 12. Kilaru S, Bergqvist AG. Current treatment of myoclonic astatic epilepsy: clinical experience at the Children’s Hospital of Philadelphia. Epilepsia 2007;48:1703-7. http://dx.doi.org/10.1111/j.1528-1167.2007.01186.x PMid:17651420
13. 13. Striano P, Coppola A, Pezzella M, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 2007;69:250-4. http://dx.doi.org/10.1212/01.wnl.0000265222.24102.db PMid:17636062
14. 14. Muslu B, Kilci O, Horasanli E, Dikmen B. Dramatic effect of levetiracetam on posthypoxic myoclonus: difficult weaning from mechanical ventilation. Clin Neuropharmacol 2009;32:236. http://dx.doi.org/10.1097/01.wnf.0000265978.72772.2d PMid:19644236
15. 15. Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010;362:790-9. http://dx.doi.org/10.1056/NEJMoa0902014 PMid:20200383 PMCid:2924476
16. 16. Hesdorffer DC, Benn EK, Cascino GD, Hauser WA. Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure. Epilepsia 2009;50:1102-8. http://dx.doi.org/10.1111/j.1528-1167.2008.01945.x PMid:19374657
17. 17. D’Ambrosio R, Perucca E. Epilepsy after head injury. Epilepsy after head injury. Curr Opin Neurol 2004;17:731-5. PMid:15542983 PMCid:2672045
18. 18. Tremont-Lukats IW, Ratilal BO, Armstrong T, Gilbert MR. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev 2008;2:CD004424. PMid:18425902